

YVONNE ERICA SCHLAEPPI

Independent Corporate Director & Former C-Suite Executive



Yvonne Schlaeppli is an international business and legal strategist known for navigating complex global business challenges across varied industries. Yvonne's collaborative leadership demonstrates strong analytical, communication and C-Suite financial skills, persistence and insight. She transitions seamlessly from strategy to operations.

Yvonne served as independent director on the boards of Ares Allergy Holdings (US) and Greer Laboratories, overseeing Compliance, from 2014 until the boards disbanded in the course of a transaction in 2015. Both companies are active in human and animal allergy immunotherapy and owned by Ares Life Sciences, a London-based investment fund with a portfolio of revenue-generating life sciences companies in Europe and the US. Ares Life Sciences is part of the Waypoint Capital Group.

Yvonne is a member of the External Advisory Committee of the Channing Division of Network Medicine at the Brigham and Women's Hospital, a Harvard Medical School-affiliated institution. The Committee is developing new strategic and financial plans for the 300+ person research division. For eight years of her New York-resident years, Yvonne served on the Board of the Swiss-American Chamber of Commerce, New York Chapter

Yvonne is well-suited to serve on the Audit, Risk, Corporate Governance or Compensation Committees of other internationally active companies. Yvonne has advised boards while General Counsel and also while an equity partner and Chair of the International Practice at the Boston law firm, Palmer & Dodge.

Yvonne has worked extensively with public and private company boards, both in the US and Europe, during periods of intense change: M&A, operational and reputational crises, and international growth. She has negotiated cross-border deals, assessed global risks, and managed IPO's, corporate governance and compliance.

Throughout her career Yvonne has led key and diverse business initiatives, such as leading negotiations of an USD 250+ M investment in a Russian manufacturing joint venture, setting strategy and establishing the first European Works Council for a US multinational with 23,000+ EU employees and evaluating and right-sizing of patent portfolios to fit existing operations and align with strategy.

As an entrepreneur as well as an advisor to entrepreneurial businesses, Yvonne is a co-founder of the international strategic advisory firm, Stratevise, where she is Managing Partner. At Stratevise, Yvonne advises on acquisitions and divestitures, industry alliances and product development principally in secure credentialing and life sciences. Among the firm's larger clients is a Fortune 200 company for which Stratevise acted as transaction advisor in an acquisition campaign.

Previously, Yvonne was General Counsel of three global groups: Global Enterprise Technologies, Passport & ID (a privately-held group with government identity and credentialing projects in more than 20 countries, which was the largest provider of digital passport printing solutions worldwide); Organon BioSciences (the spin-out of Akzo Nobel's pharma, animal health and biotech operations with USD 5+ B sales in 80 countries); and European General Counsel at Johnson Controls (the NYSE listed industrial manufacturer then with USD 4+ B in sales in the EMEA and CIS).

Yvonne is a graduate of Princeton University (the Woodrow Wilson School of Public and International Affairs). She won a German Fulbright Fellowship (DAAD) and studied at the University of Bonn. Yvonne earned her JD at Columbia University.

She is a dual US and Swiss citizen, is fluent in German and competent in French, and has spent a substantial portion of her career living and working outside the US. She currently resides in Boston.

+ 1 617 792 3403 yschlaeppli@rcn.com
www.linkedin.com/in/yvonneschlaeppli